ATRC (AtriCure) Construction In Progress: $0.0 Mil (As of Mar. 2026)


ATRC AtriCure Inc ATRC
76 GF Score
Price $28.28
GF Value $39.73
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is AtriCure Construction In Progress?

AtriCure ATRC -0.63% 76 Construction In Progress is $0.0 Mil as of Mar. 2026. GuruFocus rates ATRC with a GF Score™ of 76/100 and a GF Value™ of $39.73 (Modestly Undervalued). The stock has 1 warning sign investors should review.

AtriCure's quarterly construction in progress increased from Sep. 2025 ($0.0 Mil) to Dec. 2025 ($5.0 Mil) but then declined from Dec. 2025 ($5.0 Mil) to Mar. 2026 ($0.0 Mil).

AtriCure's annual construction in progress declined from Dec. 2023 ($7.3 Mil) to Dec. 2024 ($4.3 Mil) but then increased from Dec. 2024 ($4.3 Mil) to Dec. 2025 ($5.0 Mil).

AtriCure Construction In Progress Historical Data

* Premium members only.

The historical data trend for AtriCure's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AtriCure Construction In Progress Chart

AtriCure Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Construction In Progress
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.00 3.91 7.33 4.33 5.04

AtriCure Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Construction In Progress Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 5.04 0.00
ATRC
76GF Score
AtriCure Inc ATRC
Construction In Progress is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AtriCure Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

What does a Construction In Progress of $0.0 Mil mean?
AtriCure (ATRC) has a Construction In Progress of $0.0 Mil as of Mar. 2026. Construction in Progress records the amount of construction work that is not complete. View historical data on AtriCure and its competitors.
Is AtriCure's Construction In Progress too high?
AtriCure's current Construction In Progress is $0.0 Mil. Overall, AtriCure has a GF Score™ of 76/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does AtriCure's Construction In Progress compare to STAA and NNNN?
AtriCure's Construction In Progress of $0.0 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Construction In Progress for a Medical Devices & Instruments company?
A good Construction In Progress depends on the Medical Devices & Instruments industry context. However, Construction In Progress should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Construction In Progress mean?
A high Construction In Progress can signal that a stock is expensive relative to its fundamentals. Construction in Progress records the amount of construction work that is not complete. View historical data on AtriCure and its competitors. AtriCure's current Construction In Progress is $0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AtriCure stock overvalued right now?
Based on GuruFocus' analysis, AtriCure (ATRC) is currently considered Modestly Undervalued. The stock's GF Value™ is $39.73, compared to a current price of $28.28 — trading 28.8% below its estimated fair value. The current Construction In Progress is $0.0 Mil. AtriCure's overall GF Score™ is 76/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Construction In Progress calculated?
Construction In Progress is calculated from a company's financial statements. For AtriCure (ATRC), the current Construction In Progress is $0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is AtriCure (ATRC) Overvalued in 2026?

Based on GuruFocus' analysis, AtriCure stock appears to be undervalued. The current stock price of $28.28 is trading 28.8% below its estimated GF Value™ of $39.73. GuruFocus considers AtriCure to be Modestly Undervalued.

Key valuation signals for ATRC:

  • Construction In Progress: $0.0 Mil
  • GF Value™: $39.73 vs. price of $28.28 (28.8% below fair value)
  • GF Score™: 76/100 with 1 warning sign

No single metric tells the full story. See the ATRC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

AtriCure Business Description

Address 7555 Innovation Way, Mason, OH, USA, 45040
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation, Pacing and Sensing, and others. Geographically, it generates a majority of its revenue from the United States. Cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures.
76GF Score

Get the complete analysis for ATRC

Construction In Progress is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$28.28
Price
$39.73
GF Value